摘要
肝癌是世界常见恶性肿瘤之一,其发生是多中心,多病因和多基因参与的复合过程.其目前的治疗仍以手术切除为主,而肝癌确诊时大多已属中晚期,治疗效果很差.因此开发新的分子标志物早期诊断肝癌和寻找新的基因治疗靶点成为肝癌研究的热点.缺氧诱导因子-1(HIF-1)参与肝癌发生、发展、转移及术后复发的多个环节,对肝癌的早期诊断和分子靶向治疗具有潜在的应用前景.本文就HIF-1的分子组成、活化机制以及与肝癌靶向治疗相关进展作一综述.
Hepatocellular carcinoma （HCC） is one of the most common malignant tumor in the world, with a complex process involving multi-center, multi-cause and multi-genes. Surgical resection is still the main treatment. However, the diagnosis of HCC mostly occurs at middle or advanced stage, and the prognosis is very poor. Therefore, the development of a novel molecular marker for early diagnosis and a new target for gene therapy become hot spots. Hypoxia-inducible factor-1 （HIF-1） takes part in the development, metastasis and recurrence of HCC, and it has potential applications in the early diagnosis and molecular targeted therapy of HCC. We presented a review on molecular composition, activation mechanism of HIF-1, and the targeted therapeutic approaches applied to hepatocellular carcinoma.
出处
《世界华人消化杂志》
CAS
北大核心
2008年第27期3070-3076,共7页
World Chinese Journal of Digestology
基金
江苏省卫生科技资助项目
No.H200523~~
关键词
缺氧诱导因子-1
肝癌
靶向治疗
Hypoxia-inducible factor-1
Hepatocel-lular carcinoma
Targeted therapy
